TY - JOUR
T1 - Using quantitative sensory testing to predict attrition in an interdisciplinary pain management program
T2 - a pilot study
AU - Zafereo, Jason
AU - Uhlenbrock, Brittany
AU - Watson, Seth
AU - Wang-Price, Sharon
AU - Noe, Carl
AU - Jarrett, Robin B.
AU - Meltzer, Karen J.
AU - Huang, Mu
N1 - Funding Information:
Funded by the David M Crowley Foundation and UT Southwestern School of Health Professions Interdisciplinary Research Grant. RB Jarrett is a paid consultant to the NIH, NIMH and UptoDate. RB Jarrett has equity holdings in Amgen, Johnson and Johnson, and Procter and Gamble, and her medical center charges fees for the cognitive therapy she provides to patients. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Information:
Funded by the David M Crowley Foundation and UT Southwestern School of Health Professions Interdisciplinary Research Grant. RB Jarrett is a paid consultant to the NIH, NIMH and UptoDate. RB Jarrett has equity holdings in Amgen, Johnson and Johnson, and Procter and Gamble, and her medical center charges fees for the cognitive therapy she provides to patients. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2022 Future Medicine Ltd.
PY - 2022/7
Y1 - 2022/7
N2 - Aim: To determine the extent to which quantitative sensory testing (QST) predicted attrition in an interdisciplinary pain program (IPP). Patients & methods: Participants (n = 53) enrolled in an IPP completed pretreatment assessments of QST and the PROMIS-29 quality of life survey. Results & conclusion: Compared with completers, non-completers (24.5%) reported significantly higher pain intensity (7.1, 95% CI [5.8, 8.4] versus 5.4, 95% CI [4.8, 6.1]) and cold hyperalgesia (14.6°C, 95% CI [8.8, 20.4] versus 7.5°C, 95% CI [4.8, 6.1]), with both variables also predicting attrition. This finding highlights a potentially novel and clinically significant use of QST. Higher overall pain intensity and the presence of remote cold hyperalgesia may identify patients at risk for dropping out of an IPP.
AB - Aim: To determine the extent to which quantitative sensory testing (QST) predicted attrition in an interdisciplinary pain program (IPP). Patients & methods: Participants (n = 53) enrolled in an IPP completed pretreatment assessments of QST and the PROMIS-29 quality of life survey. Results & conclusion: Compared with completers, non-completers (24.5%) reported significantly higher pain intensity (7.1, 95% CI [5.8, 8.4] versus 5.4, 95% CI [4.8, 6.1]) and cold hyperalgesia (14.6°C, 95% CI [8.8, 20.4] versus 7.5°C, 95% CI [4.8, 6.1]), with both variables also predicting attrition. This finding highlights a potentially novel and clinically significant use of QST. Higher overall pain intensity and the presence of remote cold hyperalgesia may identify patients at risk for dropping out of an IPP.
KW - attrition
KW - central sensitization
KW - chronic pain
KW - interdisciplinary pain management program
KW - quantitative sensory testing
UR - http://www.scopus.com/inward/record.url?scp=85132751766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132751766&partnerID=8YFLogxK
U2 - 10.2217/pmt-2021-0053
DO - 10.2217/pmt-2021-0053
M3 - Article
C2 - 35345888
AN - SCOPUS:85132751766
SN - 1758-1869
VL - 12
SP - 623
EP - 633
JO - Pain Management
JF - Pain Management
IS - 5
ER -